ALSEN.PAライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 5月 2024 @ 00:15):

Stats
本日の出来高	5 355.00
平均出来高	120 421
時価総額	209.47M
EPS	€0 ( 2024-03-14 )
次の収益日	( €0 ) 2024-05-23
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-4.11
ATR14	€0 (0.00%)

Sensorion SA 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Sensorion SA 財務諸表

Annual	2023
収益:	€4.74M
総利益:	€3.79M (79.86 %)
EPS:	€-0.170

FY	2023
収益:	€4.74M
総利益:	€3.79M (79.86 %)
EPS:	€-0.170

FY	2022
収益:	€4.93M
総利益:	€4.16M (84.38 %)
EPS:	€-0.290

FY	2021
収益:	€3.34M
総利益:	€0.00 (0.00 %)
EPS:	€-0.190

Financial Reports:

No articles found.

Sensorion SA

Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.